The DOI matches its Crossref record; 335 of the 335 references it cites were found in a registry or an index.
AAV vectors: The Rubik’s cube of human gene therapy
Open accessAbstract
Defective genes account for ∼80% of the total of more than 7,000 diseases known to date. Gene therapy brings the promise of a one-time treatment option that will fix the errors in patient genetic coding. Recombinant viruses are highly efficient vehicles for in vivo gene delivery. Adeno-associated virus (AAV) vectors offer unique advantages, such as tissue tropism, specificity in transduction, eliciting of a relatively low immune responses, no incorporation into the host chromosome, and long-lasting delivered gene expression, making them the most popular viral gene delivery system in clinical trials, with three AAV-based gene therapy drugs already approved by the US Food and Drug Administration (FDA) or European Medicines Agency (EMA). Despite the success of AAV vectors, their usage in particular scenarios is still limited due to remaining challenges, such as poor transduction efficiency in certain tissues, low organ specificity, pre-existing humoral immunity to AAV capsids, and vector dose-dependent toxicity in patients. In the present review, we address the different approaches to improve AAV vectors for gene therapy with a focus on AAV capsid selection and engineering, strategies to overcome anti-AAV immune response, and vector genome design, ending with a glimpse at vector production methods and the current state of recombinant AAV (rAAV) at the clinical level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
Adeno-associated virus vector as a platform for gene therapy delivery
Wang, D., Tai, P. W. L., & Gao, G. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0012-9 · Cited by 2,444
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Adenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864 · cited 1×
“12,194,198,210 The most common course of treatment has been corticosteroid administration, 12,196,210 which has not always been successful to control anti-AAV immune responses and has known side effects.”
BackgroundAdding New Chemistries to the Genetic Code
Liu, C. C., & Schultz, P. G. (2010) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.052308.105824 · Cited by 1,725 · cited 1×
“154,155 The unnatural amino acid AzK was chosen (by its azido functionality, which enables a highly speci fi c bioconjugation reaction) to be introduced in distinct surface-exposed sites of AAV2.”
BackgroundChan, K. Y., Jang, M. J., Yoo, B. B., Greenbaum, A., Ravi, N., Wu, W.-L., Sánchez-Guardado, L., Lois, C., Mazmanian, S. K., Deverman, B. E., et al. (2017) · Nature Neuroscience · doi:10.1038/nn.4593 · Cited by 1,578
Analysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490
Long-Term Safety and Efficacy of Factor IX Gene Therapy in Hemophilia B
Nathwani, A. C., Reiss, U. M., Tuddenham, E. G. D., Rosales, C., Chowdary, P., McIntosh, J., Della Peruta, M., Lheriteau, E., Patel, N., Raj, D., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407309 · Cited by 1,273
Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain
Deverman, B. E., Pravdo, P. L., Simpson, B. P., Kumar, S. R., Chan, K. Y., Banerjee, A., Wu, W.-L., Yang, B., Huber, N., Pasca, S. P., et al. (2016) · Nature Biotechnology · doi:10.1038/nbt.3440 · Cited by 1,061
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Adenovirus-Associated Defective Virus Particles
Atchison, R. W., Casto, B. C., & Hammon, W. M. (1965) · Science · doi:10.1126/science.149.3685.754 · Cited by 1,004
Lunn, M. R., & Wang, C. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60921-6 · Cited by 995
Boutin, S., Monteilhet, V., Veron, P., Leborgne, C., Benveniste, O., Montus, M. F., & Masurier, C. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.182 · Cited by 970
Emerging issues in AAV-mediated in vivo gene therapy
Colella, P., Ronzitti, G., & Mingozzi, F. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2017.11.007 · Cited by 881
Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808
Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant
George, L. A., Sullivan, S. K., Giermasz, A., Rasko, J. E. J., Samelson-Jones, B. J., Ducore, J., Cuker, A., Sullivan, L. M., Majumdar, S., Teitel, J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708538 · Cited by 762
Molecular evolution by staggered extension process (StEP) in vitro recombination
Zhao, H., Giver, L., Shao, Z., Affholter, J. A., & Arnold, F. H. (1998) · Nature Biotechnology · doi:10.1038/nbt0398-258 · Cited by 757
Cd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Grimm, D., Lee, J. S., Wang, L., Desai, T., Akache, B., Storm, T. A., & Kay, M. A. (2008) · Journal of Virology · doi:10.1128/jvi.00254-08 · Cited by 696
Zhong, L., Li, B., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Cooper, M., Herzog, R. W., Zolotukhin, I., Warrington, K. H., Weigel-Van Aken, K. A., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802866105 · Cited by 558 · cited 2×
“64,65 A triple-mutant (Y444F + Y500F + Y730F) vector has (cid:1) 30-to 80-fold higher level of in vivo gene transfer to murine hepatocytes 66 and (cid:1) 130-fold increase in transgene expression in murine fi broblasts 67 than the wild-type AAV2.”
BackgroundDirected evolution of adeno-associated virus yields enhanced gene delivery vectors
Maheshri, N., Koerber, J. T., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Biotechnology · doi:10.1038/nbt1182 · Cited by 538 · cited 1×
“95,121,122 To improve the liver transduction of AAV5 while retaining its low seroprevalence, a library of AAV5 mutants was constructed via random mutagenesis and screened in Huh7 cells.”
BackgroundAn essential receptor for adeno-associated virus infection
Pillay, S., Meyer, N. L., Puschnik, A. S., Davulcu, O., Diep, J., Ishikawa, Y., Jae, L. T., Wosen, J. E., Nagamine, C. M., Chapman, M. S., et al. (2016) · Nature · doi:10.1038/nature16465 · Cited by 532
Gray, S. J., Matagne, V., Bachaboina, L., Yadav, S., Ojeda, S. R., & Samulski, R. J. (2011) · Molecular Therapy · doi:10.1038/mt.2011.72 · Cited by 501
Self-citationNew recombinant serotypes of AAV vectors
Gao, G., Vandenberghe, L., & Wilson, J. (2005) · Current Gene Therapy · doi:10.2174/1566523054065057 · Cited by 487
Brown, B. D., Venneri, M. A., Zingale, A., Sergi, L. S., & Naldini, L. (2006) · Nature Medicine · doi:10.1038/nm1398 · Cited by 484
Designing logical codon reassignment – Expanding the chemistry in biology
Dumas, A., Lercher, L., Spicer, C. D., & Davis, B. G. (2015) · Chemical Science · doi:10.1039/c4sc01534g · Cited by 482
The AAV Vector Toolkit: Poised at the Clinical Crossroads
Asokan, A., Schaffer, D. V., & Jude Samulski, R. (2012) · Molecular Therapy · doi:10.1038/mt.2011.287 · Cited by 465
Insect Cells as a Factory to Produce Adeno-Associated Virus Type 2 Vectors
Urabe, M., Ding, C., & Kotin, R. M. (2002) · Human Gene Therapy · doi:10.1089/10430340260355347 · Cited by 457
Jun-ichi, M., Satoshi, T., Kimi, A., Fumi, T., Akira, T., Kiyoshi, T., & Ken-ichi, Y. (1989) · Gene · doi:10.1016/0378-1119(89)90209-6 · Cited by 446
Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., & Srivastava, A. (1999) · Nature Medicine · doi:10.1038/4758 · Cited by 443
Akache, B., Grimm, D., Pandey, K., Yant, S. R., Xu, H., & Kay, M. A. (2006) · Journal of Virology · doi:10.1128/jvi.00878-06 · Cited by 430
The Neurotropic Properties of AAV-PHP.B Are Limited to C57BL/6J Mice
Hordeaux, J., Wang, Q., Katz, N., Buza, E. L., Bell, P., & Wilson, J. M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.018 · Cited by 426 · cited 2×
“142 Intravenous administration of PHP.”
MethodGrieger, J. C., & Samulski, R. J. (2005) · Journal of Virology · doi:10.1128/jvi.79.15.9933-9944.2005 · Cited by 419
Self-citationMüller, O. J., Kaul, F., Weitzman, M. D., Pasqualini, R., Arap, W., Kleinschmidt, J. A., & Trepel, M. (2003) · Nature Biotechnology · doi:10.1038/nbt856 · Cited by 410
Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
Girod, A., Ried, M., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deléage, G., & Hallek, M. (1999) · Nature Medicine · doi:10.1038/12491 · Cited by 405
Phase 1 Gene Therapy for Duchenne Muscular Dystrophy Using a Translational Optimized AAV Vector
Bowles, D. E., McPhee, S. W., Li, C., Gray, S. J., Samulski, J. J., Camp, A. S., Li, J., Wang, B., Monahan, P. E., Rabinowitz, J. E., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.237 · Cited by 400
Self-citationWu, P., Xiao, W., Conlon, T., Hughes, J., Agbandje-McKenna, M., Ferkol, T., Flotte, T., & Muzyczka, N. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8635-8647.2000 · Cited by 390
Thomas, C. E., Storm, T. A., Huang, Z., & Kay, M. A. (2004) · Journal of Virology · doi:10.1128/jvi.78.6.3110-3122.2004 · Cited by 358 · cited 1×
“53,54 Several reports summarize and review the transduction ef fi cacy of AAV serotypes in different tissues and speci fi c cells.”
BackgroundHuman Immune Responses to Adeno-Associated Virus (AAV) Vectors
Ronzitti, G., Gross, D.-A., & Mingozzi, F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00670 · Cited by 357
Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design
Ogden, P. J., Kelsic, E. D., Sinai, S., & Church, G. M. (2019) · Science · doi:10.1126/science.aaw2900 · Cited by 356
A generic intron increases gene expression in transgenic mice.
Choi, T., Huang, M., Gorman, C., & Jaenisch, R. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.6.3070 · Cited by 356
In vivo tissue-tropism of adeno-associated viral vectors
Srivastava, A. (2016) · Current Opinion in Virology · doi:10.1016/j.coviro.2016.08.003 · Cited by 347
Gene Therapy Leaves a Vicious Cycle
Goswami, R., Subramanian, G., Silayeva, L., Newkirk, I., Doctor, D., Chawla, K., Chattopadhyay, S., Chandra, D., Chilukuri, N., & Betapudi, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00297 · Cited by 347
Nathwani, A. C., Rosales, C., McIntosh, J., Rastegarlari, G., Nathwani, D., Raj, D., Nawathe, S., Waddington, S. N., Bronson, R., Jackson, S., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2010.274 · Cited by 345
Flotte, T. R., Afione, S. A., Solow, R., Drumm, M. L., Markakis, D., Guggino, W. B., Zeitlin, P. L., & Carter, B. J. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)53762-5 · Cited by 342
Leborgne, C., Barbon, E., Alexander, J. M., Hanby, H., Delignat, S., Cohen, D. M., Collaud, F., Muraleetharan, S., Lupo, D., Silverberg, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0911-7 · Cited by 336
Zhu, J., Huang, X., & Yang, Y. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37607 · Cited by 330
Grieger, J. C., Soltys, S. M., & Samulski, R. J. (2016) · Molecular Therapy · doi:10.1038/mt.2015.187 · Cited by 325
Self-citationTrans-splicing vectors expand the utility of adeno-associated virus for gene therapy
Yan, Z., Zhang, Y., Duan, D., & Engelhardt, J. F. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.12.6716 · Cited by 305
Gene Therapy With Adeno-Associated Virus Vector 5-Human Factor IX in Adults With Hemophilia B
Miesbach, W., Meijer, K., Coppens, M., Kampmann, P., Klamroth, R., Schutgens, R., Tangelder, M., Castaman, G., Schwäble, J., Bonig, H., et al. (2018) · Blood · doi:10.1182/blood-2017-09-804419 · Cited by 301
Deep diversification of an AAV capsid protein by machine learning
Bryant, D. H., Bashir, A., Sinai, S., Jain, N. K., Ogden, P. J., Riley, P. F., Church, G. M., Colwell, L. J., & Kelsic, E. D. (2021) · Nature Biotechnology · doi:10.1038/s41587-020-00793-4 · Cited by 300
Zhang, H., Yang, B., Mu, X., Ahmed, S. S., Su, Q., He, R., Wang, H., Mueller, C., Sena-Esteves, M., Brown, R., et al. (2011) · Molecular Therapy · doi:10.1038/mt.2011.98 · Cited by 291
Microvesicle-associated AAV Vector as a Novel Gene Delivery System
Maguire, C. A., Balaj, L., Sivaraman, S., Crommentuijn, M. H., Ericsson, M., Mincheva-Nilsson, L., Baranov, V., Gianni, D., Tannous, B. A., Sena-Esteves, M., et al. (2012) · Molecular Therapy · doi:10.1038/mt.2011.303 · Cited by 283
Hastie, E., & Samulski, R. J. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.025 · Cited by 280
Self-citationEffective delivery of large genes to the retina by dual AAV vectors
Trapani, I., Colella, P., Sommella, A., Iodice, C., Cesi, G., de Simone, S., Marrocco, E., Rossi, S., Giunti, M., Palfi, A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302948 · Cited by 269
Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization
Sun, L., Li, J., & Xiao, X. (2000) · Nature Medicine · doi:10.1038/75087 · Cited by 267
Asokan, A., Conway, J. C., Phillips, J. L., Li, C., Hegge, J., Sinnott, R., Yadav, S., DiPrimio, N., Nam, H.-J., Agbandje-McKenna, M., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1599 · Cited by 266
Self-citationMeliani, A., Boisgerault, F., Hardet, R., Marmier, S., Collaud, F., Ronzitti, G., Leborgne, C., Costa Verdera, H., Simon Sola, M., Charles, S., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06621-3 · Cited by 265
Duan, D., Yue, Y., & Engelhardt, J. F. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0456 · Cited by 262
Systematic gene tagging using CRISPR/Cas9 in human stem cells to illuminate cell organization
Roberts, B., Haupt, A., Tucker, A., Grancharova, T., Arakaki, J., Fuqua, M. A., Nelson, A., Hookway, C., Ludmann, S. A., Mueller, I. A., et al. (2017) · Molecular Biology of the Cell · doi:10.1091/mbc.e17-03-0209 · Cited by 262
Li, W., Asokan, A., Wu, Z., Van Dyke, T., DiPrimio, N., Johnson, J. S., Govindaswamy, L., Agbandje-McKenna, M., Leichtle, S., Eugene Redmond Jr, D., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.100 · Cited by 261
Self-citationCRISPR/Cas9‐mediated genome engineering: An adeno‐associated viral (AAV) vector toolbox
Senís, E., Fatouros, C., Große, S., Wiedtke, E., Niopek, D., Mueller, A., Börner, K., & Grimm, D. (2014) · Biotechnology Journal · doi:10.1002/biot.201400046 · Cited by 260
Weinmann, J., Weis, S., Sippel, J., Tulalamba, W., Remes, A., El Andari, J., Herrmann, A.-K., Pham, Q. H., Borowski, C., Hille, S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19230-w · Cited by 259
Cell Lines for the Production of Recombinant Adeno-Associated Virus
Clark, K. R., Voulgaropoulou, F., Fraley, D. M., & Johnson, P. R. (1995) · Human Gene Therapy · doi:10.1089/hum.1995.6.10-1329 · Cited by 257
CpG-depleted adeno-associated virus vectors evade immune detection
Faust, S. M., Bell, P., Cutler, B. J., Ashley, S. N., Zhu, Y., Rabinowitz, J. E., & Wilson, J. M. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68205 · Cited by 254
Mori, S., Wang, L., Takeuchi, T., & Kanda, T. (2004) · Virology · doi:10.1016/j.virol.2004.10.012 · Cited by 245
Rescue of hearing by gene delivery to inner-ear hair cells using exosome-associated AAV
György, B., Sage, C., Indzhykulian, A. A., Scheffer, D. I., Brisson, A. R., Tan, S., Wu, X., Volak, A., Mu, D., Tamvakologos, P. I., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.12.010 · Cited by 243
Incorporation of Tumor-Targeting Peptides into Recombinant Adeno-associated Virus Capsids
Grifman, M., Trepel, M., Speece, P., Gilbert, L. B., Arap, W., Pasqualini, R., & Weitzman, M. D. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0345 · Cited by 241
Wu, Z., Asokan, A., Grieger, J. C., Govindasamy, L., Agbandje-McKenna, M., & Samulski, R. J. (2006) · Journal of Virology · doi:10.1128/jvi.01288-06 · Cited by 237
Self-citationHuang, Q., Chan, K. Y., Tobey, I. G., Chan, Y. A., Poterba, T., Boutros, C. L., Balazs, A. B., Daneman, R., Bloom, J. M., Seed, C., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0225206 · Cited by 234 · cited 4×
“143 The absence of LY6A in some mouse strains and primates explained the failure to reproduce the reported neurotropic effects previously observed in C57BL/6J mice.”
BackgroundInfluentialZhong, L., Li, B., Jayandharan, G., Mah, C. S., Govindasamy, L., Agbandje-McKenna, M., Herzog, R. W., Weigel-Van Aken, K. A., Hobbs, J. A., Zolotukhin, S., et al. (2008) · Virology · doi:10.1016/j.virol.2008.08.027 · Cited by 232
Characterization of Genome Integrity for Oversized Recombinant AAV Vector
Dong, B., Nakai, H., & Xiao, W. (2010) · Molecular Therapy · doi:10.1038/mt.2009.258 · Cited by 230
Bartlett, J. S., Kleinschmidt, J., Boucher, R. C., & Samulski, R. J. (1999) · Nature Biotechnology · doi:10.1038/6185 · Cited by 230
Self-citationEfficient in vivo gene expression by trans-splicing adeno-associated viral vectors
Lai, Y., Yue, Y., Liu, M., Ghosh, A., Engelhardt, J. F., Chamberlain, J. S., & Duan, D. (2005) · Nature Biotechnology · doi:10.1038/nbt1153 · Cited by 224
Optimization of DNA shuffling for high fidelity recombination
Zhao, H. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.6.1307 · Cited by 221
Hösel, M., Broxtermann, M., Janicki, H., Esser, K., Arzberger, S., Hartmann, P., Gillen, S., Kleeff, J., Stabenow, D., Odenthal, M., et al. (2012) · Hepatology · doi:10.1002/hep.24625 · Cited by 219
Davidoff, A. M., Gray, J. T., Ng, C. Y. C., Zhang, Y., Zhou, J., Spence, Y., Bakar, Y., & Nathwani, A. C. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.12.022 · Cited by 218
The GPI-Linked Protein LY6A Drives AAV-PHP.B Transport across the Blood-Brain Barrier
Hordeaux, J., Yuan, Y., Clark, P. M., Wang, Q., Martino, R. A., Sims, J. J., Bell, P., Raymond, A., Stanford, W. L., & Wilson, J. M. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.013 · Cited by 217
Engineering adeno-associated viral vectors to evade innate immune and inflammatory responses
Chan, Y. K., Wang, S. K., Chu, C. J., Copland, D. A., Letizia, A. J., Costa Verdera, H., Chiang, J. J., Sethi, M., Wang, M. K., Neidermyer, W. J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd3438 · Cited by 215 · cited 2×
“204 205 – 207 Faust et al. showed that CpG-depleted AAVrh32.”
BackgroundAAV Capsid Structure and Cell Interactions
Agbandje-McKenna, M., & Kleinschmidt, J. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-370-7_3 · Cited by 215
Adeno-associated virus capsid assembly is divergent and stochastic
Wörner, T. P., Bennett, A., Habka, S., Snijder, J., Friese, O., Powers, T., Agbandje-McKenna, M., & Heck, A. J. R. (2021) · Nature Communications · doi:10.1038/s41467-021-21935-5 · Cited by 215
Yang, B., Li, S., Wang, H., Guo, Y., Gessler, D. J., Cao, C., Su, Q., Kramer, J., Zhong, L., Ahmed, S. S., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.68 · Cited by 213
Rational design of a super core promoter that enhances gene expression
Juven-Gershon, T., Cheng, S., & Kadonaga, J. T. (2006) · Nature Methods · doi:10.1038/nmeth937 · Cited by 209
Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid
Vandenberghe, L. H., Wang, L., Somanathan, S., Zhi, Y., Figueredo, J., Calcedo, R., Sanmiguel, J., Desai, R. A., Chen, C. S., Johnston, J., et al. (2006) · Nature Medicine · doi:10.1038/nm1445 · Cited by 208
Novel AAV serotypes for improved ocular gene transfer
Lebherz, C., Maguire, A., Tang, W., Bennett, J., & Wilson, J. M. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1126 · Cited by 208
Monteilhet, V., Saheb, S., Boutin, S., Leborgne, C., Veron, P., Montus, M.-F., Moullier, P., Benveniste, O., & Masurier, C. (2011) · Molecular Therapy · doi:10.1038/mt.2011.108 · Cited by 206
Warrington, K. H., Gorbatyuk, O. S., Harrison, J. K., Opie, S. R., Zolotukhin, S., & Muzyczka, N. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6595-6609.2004 · Cited by 205
Optimization of the helper-dependent adenovirus system for production and potency in vivo
Sandig, V., Youil, R., Bett, A. J., Franlin, L. L., Oshima, M., Maione, D., Wang, F., Metzker, M. L., Savino, R., & Caskey, C. T. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.3.1002 · Cited by 202
Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles
Kishimoto, T. K., Ferrari, J. D., LaMothe, R. A., Kolte, P. N., Griset, A. P., O'Neil, C., Chan, V., Browning, E., Chalishazar, A., Kuhlman, W., et al. (2016) · Nature Nanotechnology · doi:10.1038/nnano.2016.135 · Cited by 201
Duan, D., Yue, Y., Yan, Z., & Engelhardt, J. F. (2000) · Nature Medicine · doi:10.1038/75080 · Cited by 200
Kronenberg, S., Böttcher, B., von der Lieth, C. W., Bleker, S., & Kleinschmidt, J. A. (2005) · Journal of Virology · doi:10.1128/jvi.79.9.5296-5303.2005 · Cited by 198
Visual Acuity after Retinal Gene Therapy for Choroideremia
Edwards, T. L., Jolly, J. K., Groppe, M., Barnard, A. R., Cottriall, C. L., Tolmachova, T., Black, G. C., Webster, A. R., Lotery, A. J., Holder, G. E., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmc1509501 · Cited by 195
Tornabene, P., Trapani, I., Minopoli, R., Centrulo, M., Lupo, M., de Simone, S., Tiberi, P., Dell’Aquila, F., Marrocco, E., Iodice, C., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav4523 · Cited by 192
Influence of Pre-existing Anti-capsid Neutralizing and Binding Antibodies on AAV Vector Transduction
Fitzpatrick, Z., Leborgne, C., Barbon, E., Masat, E., Ronzitti, G., van Wittenberghe, L., Vignaud, A., Collaud, F., Charles, S., Simon Sola, M., et al. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.02.003 · Cited by 192
Structural Proteins of Adenovirus-Associated Viruses
Rose, J. A., Maizel, J. V., Inman, J. K., & Shatkin, A. J. (1971) · Journal of Virology · doi:10.1128/jvi.8.5.766-770.1971 · Cited by 190
Konkle, B. A., Walsh, C. E., Escobar, M. A., Josephson, N. C., Young, G., von Drygalski, A., McPhee, S. W. J., Samulski, R. J., Bilic, I., de la Rosa, M., et al. (2021) · Blood · doi:10.1182/blood.2019004625 · Cited by 189
Self-citationGenetic risk assessment in carrier testing for spinal muscular atrophy
Ogino, S., Leonard, D. G. B., Rennert, H., Ewens, W. J., & Wilson, R. B. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10425 · Cited by 189
Choi, J.-H., Yu, N.-K., Baek, G.-C., Bakes, J., Seo, D., Nam, H. J., Baek, S. H., Lim, C.-S., Lee, Y.-S., & Kaang, B.-K. (2014) · Molecular Brain · doi:10.1186/1756-6606-7-17 · Cited by 188
Pillay, S., Zou, W., Cheng, F., Puschnik, A. S., Meyer, N. L., Ganaie, S. S., Deng, X., Wosen, J. E., Davulcu, O., Yan, Z., et al. (2017) · Journal of Virology · doi:10.1128/jvi.00391-17 · Cited by 187
Al-Zaidy, S. A., Kolb, S. J., Lowes, L., Alfano, L. N., Shell, R., Church, K. R., Nagendran, S., Sproule, D. M., Feltner, D. E., Wells, C., et al. (2019) · Journal of Neuromuscular Diseases · doi:10.3233/jnd-190403 · Cited by 185
Gray, S. J., Blake, B. L., Criswell, H. E., Nicolson, S. C., Samulski, R. J., & McCown, T. J. (2010) · Molecular Therapy · doi:10.1038/mt.2009.292 · Cited by 185
Self-citationExpanded Repertoire of AAV Vector Serotypes Mediate Unique Patterns of Transduction in Mouse Brain
Cearley, C. N., Vandenberghe, L. H., Parente, M. K., Carnish, E. R., Wilson, J. M., & Wolfe, J. H. (2008) · Molecular Therapy · doi:10.1038/mt.2008.166 · Cited by 182 · cited 1×
“34 Tissue tropism re fl ects the speci fi c interactions between serotype-speci fi c structures on the rAAVcapsidandcellularglycans andreceptors.”
BackgroundKruzik, A., Fetahagic, D., Hartlieb, B., Dorn, S., Koppensteiner, H., Horling, F. M., Scheiflinger, F., Reipert, B. M., & de la Rosa, M. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.014 · Cited by 182
Chen, Z.-Y., He, C.-Y., & Kay, M. A. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.126 · Cited by 180
Münch, R. C., Janicki, H., Völker, I., Rasbach, A., Hallek, M., Büning, H., & Buchholz, C. J. (2013) · Molecular Therapy · doi:10.1038/mt.2012.186 · Cited by 179
Schiedner, G., Hertel, S., & Kochanek, S. (2000) · Human Gene Therapy · doi:10.1089/104303400750001417 · Cited by 178
Pharmacology of Recombinant Adeno-associated Virus Production
Penaud-Budloo, M., François, A., Clément, N., & Ayuso, E. (2018) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.002 · Cited by 177
Self-citationNakai, H., Storm, T. A., & Kay, M. A. (2000) · Nature Biotechnology · doi:10.1038/75390 · Cited by 176
Matsuzaki, Y., Konno, A., Mochizuki, R., Shinohara, Y., Nitta, K., Okada, Y., & Hirai, H. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2017.11.049 · Cited by 173 · cited 1×
“144 Nevertheless, AAV-PHP.”
Rabinowitz, J. E., Bowles, D. E., Faust, S. M., Ledford, J. G., Cunningham, S. E., & Samulski, R. J. (2004) · Journal of Virology · doi:10.1128/jvi.78.9.4421-4432.2004 · Cited by 171
Self-citationRumachik, N. G., Malaker, S. A., Poweleit, N., Maynard, L. H., Adams, C. M., Leib, R. D., Cirolia, G., Thomas, D. R., Stamnes, S. J., Holt, K. H., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.05.018 · Cited by 170
PEG conjugation moderately protects adeno‐associated viral vectors against antibody neutralization
Lee, G. K., Maheshri, N., Kaspar, B., & Schaffer, D. V. (2005) · Biotechnology and Bioengineering · doi:10.1002/bit.20562 · Cited by 169 · cited 3×
“149 Masking of arginine residues on AAV capsids can be achieved by an exogenous glycation reaction, in which surface-exposed guanidinium side chains are modi fi ed into charge neutral hydroimidazolones.”
BackgroundInfluentialRapid evolution of blood-brain-barrier-penetrating AAV capsids by RNA-driven biopanning
Nonnenmacher, M., Wang, W., Child, M. A., Ren, X.-Q., Huang, C., Ren, A. Z., Tocci, J., Chen, Q., Bittner, K., Tyson, K., et al. (2021) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.12.006 · Cited by 168 · cited 2×
“148 It remains to be seen whether this or equivalent methodologies will allow the selection of better vectors for human use.”
BackgroundMethodSnijder, J., van de Waterbeemd, M., Damoc, E., Denisov, E., Grinfeld, D., Bennett, A., Agbandje-McKenna, M., Makarov, A., & Heck, A. J. R. (2014) · Journal of the American Chemical Society · doi:10.1021/ja502616y · Cited by 168
Rincon, M. Y., VandenDriessche, T., & Chuah, M. K. (2015) · Cardiovascular Research · doi:10.1093/cvr/cvv205 · Cited by 167
Wassmer, S. J., Carvalho, L. S., György, B., Vandenberghe, L. H., & Maguire, C. A. (2017) · Scientific Reports · doi:10.1038/srep45329 · Cited by 164 · cited 2×
“169 An intratumoral administration of AAV6 vexosomes carrying a suicide gene in a murine xenograft model revealed a 2.3-fold increase in hepatocellular carcinoma regression compared with untreated animals.”
BackgroundInfluentialShi, W., & Bartlett, J. S. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00042-x · Cited by 164
Ghosh, A., Yue, Y., Lai, Y., & Duan, D. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300322 · Cited by 161
Generation and characterization of chimeric recombinant AAV vectors
Hauck, B., Chen, L., & Xiao, W. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00012-1 · Cited by 160
Hammond, S. L., Leek, A. N., Richman, E. H., & Tjalkens, R. B. (2017) · PLOS ONE · doi:10.1371/journal.pone.0188830 · Cited by 160
Adeno-associated virus serotypes for gene therapeutics
Lisowski, L., Tay, S. S., & Alexander, I. E. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.07.006 · Cited by 159
Li, Z., Zhao, W., Wu, J., Li, B., Zolotukhin, S., Govindasamy, L., Agbandje‐McKenna, M., & Srivastava, A. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300170 · Cited by 156
Rumachik, N. G., Malaker, S. A., Poweleit, N., Maynard, L. H., Adams, C. M., Leib, R. D., Cirolia, G., Thomas, D., Stamnes, S., Holt, K., et al. (2019) · doi:10.1101/640169 · Cited by 156
Wu, Z., Sun, J., Zhang, T., Yin, C., Yin, F., Van Dyke, T., Samulski, R. J., & Monahan, P. E. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300355 · Cited by 153
Self-citationGyörgy, B., Fitzpatrick, Z., Crommentuijn, M. H. W., Mu, D., & Maguire, C. A. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.05.032 · Cited by 153
Bigger, B., Tolmachov, O. E., Collombet, J.-M., Fragkos, M., Palaszewski, I., & Coutelle, C. C. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010873200 · Cited by 149
Schambach, A., Mueller, D., Galla, M., Verstegen, M. M. A., Wagemaker, G., Loew, R., Baum, C., & Bohne, J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302807 · Cited by 148
Exosome-associated AAV vector as a robust and convenient neuroscience tool
Hudry, E., Martin, C., Gandhi, S., György, B., Scheffer, D. I., Mu, D., Merkel, S. F., Mingozzi, F., Fitzpatrick, Z., Dimant, H., et al. (2016) · Gene Therapy · doi:10.1038/gt.2016.11 · Cited by 146
GPR108 Is a Highly Conserved AAV Entry Factor
Dudek, A. M., Zabaleta, N., Zinn, E. M., Pillay, S., Zengel, J. R., Porter, C. L., Franceschini, J. S., Estelien, R., Carette, J. E., Zhou, G. L., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.005 · Cited by 144
Khani, S. C., Pawlyk, B. S., Bulgakov, O. V., Kasperek, E. M., Young, J. E., Adamian, M., Sun, X., Smith, A. J., Ali, R. R., & Li, T. (2007) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.07-0257 · Cited by 143
Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6
Weller, M. L., Amornphimoltham, P., Schmidt, M., Wilson, P. A., Gutkind, J. S., & Chiorini, J. A. (2010) · Nature Medicine · doi:10.1038/nm.2145 · Cited by 140
B-cell depletion is protective against anti-AAV capsid immune response: a human subject case study
Corti, M., Elder, M., Falk, D., Lawson, L., Smith, B., Nayak, S., Conlon, T., Clément, N., Erger, K., Lavassani, E., et al. (2014) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2014.33 · Cited by 140
Horowitz, E. D., Rahman, K. S., Bower, B. D., Dismuke, D. J., Falvo, M. R., Griffith, J. D., Harvey, S. C., & Asokan, A. (2013) · Journal of Virology · doi:10.1128/jvi.03017-12 · Cited by 139 · cited 1×
“289 Thus, lower size vectors may have lower potency than wild-type size vectors independently of transgene cassette design due to reduced transgene delivery in the target cell nucleus.”
BackgroundHaberman, R. P., McCown, T. J., & Samulski, R. J. (2000) · Journal of Virology · doi:10.1128/jvi.74.18.8732-8739.2000 · Cited by 139
Self-citationLarge-scale recombinant adeno-associated virus production
Kotin, R. M. (2011) · Human Molecular Genetics · doi:10.1093/hmg/ddr141 · Cited by 137
Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme
Elmore, Z. C., Oh, D. K., Simon, K. E., Fanous, M. M., & Asokan, A. (2020) · JCI Insight · doi:10.1172/jci.insight.139881 · Cited by 137
Insertional Mutagenesis of AAV2 Capsid and the Production of Recombinant Virus
Rabinowitz, J. E., Xiao, W., & Samulski, R. J. (1999) · Virology · doi:10.1006/viro.1999.0045 · Cited by 136
Self-citationCombinatorial engineering of a gene therapy vector: directed evolution of adeno‐associated virus
Perabo, L., Endell, J., King, S., Lux, K., Goldnau, D., Hallek, M., & Büning, H. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.849 · Cited by 136
Perabò, L., Goldnau, D., White, K., Endell, J., Bouças, J., Humme, S., Work, L. M., Janicki, H., Hallek, M. J., Baker, A. H., et al. (2006) · Journal of Virology · doi:10.1128/jvi.00076-06 · Cited by 136
Erratum: Genetic capsid modifications allow efficient re-targeting of adeno-associated virus type 2
Girod, A., Ried, M. U., Wobus, C., Lahm, H., Leike, K., Kleinschmidt, J., Deléage, G., & Hallek, M. J. (1999) · Nature Medicine · doi:10.1038/71021 · Cited by 136
Adeno-associated virus: fit to serve
Zinn, E. M., & Vandenberghe, L. H. (2014) · Current Opinion in Virology · doi:10.1016/j.coviro.2014.07.008 · Cited by 134
Rogers, G. L., Shirley, J. L., Zolotukhin, I., Kumar, S. R. P., Sherman, A., Perrin, G. Q., Hoffman, B. E., Srivastava, A., Basner-Tschakarjan, E., Wallet, M. A., et al. (2017) · Blood · doi:10.1182/blood-2016-11-751040 · Cited by 131
Markusic, D. M., Herzog, R. W., Aslanidi, G. V., Hoffman, B. E., Li, B., Li, M., Jayandharan, G. R., Ling, C., Zolotukhin, I., Ma, W., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.172 · Cited by 131 · cited 1×
“64,65 A triple-mutant (Y444F + Y500F + Y730F) vector has (cid:1) 30-to 80-fold higher level of in vivo gene transfer to murine hepatocytes 66 and (cid:1) 130-fold increase in transgene expression in murine fi broblasts 67 than the wild-type AAV2.”
BackgroundYang, Q., Mamounas, M. J., Yu, G., Kennedy, S. P., Leaker, B. R., Merson, J. R., Wong‐Staal, F., Yu, M., & Barber, J. R. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.13-1929 · Cited by 131
The Pleiotropic Effects of Natural AAV Infections on Liver-directed Gene Transfer in Macaques
Wang, L., Calcedo, R., Wang, H., Bell, P., Grant, R., Vandenberghe, L. H., Sanmiguel, J., Morizono, H., Batshaw, M. L., & Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.245 · Cited by 130
Triple Vectors Expand AAV Transfer Capacity in the Retina
Maddalena, A., Tornabene, P., Tiberi, P., Minopoli, R., Manfredi, A., Mutarelli, M., Rossi, S., Simonelli, F., Naggert, J. K., Cacchiarelli, D., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.11.019 · Cited by 128
Meliani, A., Boisgerault, F., Fitzpatrick, Z., Marmier, S., Leborgne, C., Collaud, F., Simon Sola, M., Charles, S., Ronzitti, G., Vignaud, A., et al. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017010181 · Cited by 127
Majowicz, A., Nijmeijer, B., Lampen, M. H., Spronck, L., de Haan, M., Petry, H., van Deventer, S. J., Meyer, C., Tangelder, M., & Ferreira, V. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.05.009 · Cited by 126
Huttner, N. A., Girod, A., Perabo, L., Edbauer, D., Kleinschmidt, J. A., Büning, H., & Hallek, M. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302123 · Cited by 124
Characterization of Tissue Tropism Determinants of Adeno-Associated Virus Type 1
Hauck, B., & Xiao, W. (2003) · Journal of Virology · doi:10.1128/jvi.77.4.2768-2774.2003 · Cited by 124
Clément, N., Knop, D. R., & Byrne, B. J. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.094 · Cited by 124
Giles, A. R., Sims, J. J., Turner, K. B., Govindasamy, L., Alvira, M. R., Lock, M. W., & Wilson, J. M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.09.013 · Cited by 123
Adeno-Associated Virus (AAV) Versus Immune Response
Rabinowitz, J., Chan, Y. K., & Samulski, R. J. (2019) · Viruses · doi:10.3390/v11020102 · Cited by 122
Self-citationHalbert, C. L., Allen, J. M., & Miller, A. D. (2002) · Nature Biotechnology · doi:10.1038/nbt0702-697 · Cited by 121
Johnson, J. S., Li, C., DiPrimio, N., Weinberg, M. S., McCown, T. J., & Samulski, R. J. (2010) · Journal of Virology · doi:10.1128/jvi.00687-10 · Cited by 121
Self-citationNanobody-Enhanced Targeting of AAV Gene Therapy Vectors
Eichhoff, A. M., Börner, K., Albrecht, B., Schäfer, W., Baum, N., Haag, F., Körbelin, J., Trepel, M., Braren, I., Grimm, D., et al. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.09.003 · Cited by 121
Shao, W., Earley, L. F., Chai, Z., Chen, X., Sun, J., He, T., Deng, M., Hirsch, M. L., Ting, J., Samulski, R. J., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120474 · Cited by 119
Self-citationFoster, H., Sharp, P. S., Athanasopoulos, T., Trollet, C., Graham, I. R., Foster, K., Wells, D. J., & Dickson, G. (2008) · Molecular Therapy · doi:10.1038/mt.2008.186 · Cited by 119
Grimm, D., Pandey, K., Nakai, H., Storm, T. A., & Kay, M. A. (2006) · Journal of Virology · doi:10.1128/jvi.80.1.426-439.2006 · Cited by 118
Nature's recipe for splitting inteins
Aranko, A. S., Wlodawer, A., & Iwai, H. (2014) · Protein Engineering Design and Selection · doi:10.1093/protein/gzu028 · Cited by 116
After Glybera's withdrawal, what's next for gene therapy?
Senior, M. (2017) · Nature Biotechnology · doi:10.1038/nbt0617-491 · Cited by 116
Fischer, M. D., McClements, M. E., Martinez-Fernandez de la Camara, C., Bellingrath, J.-S., Dauletbekov, D., Ramsden, S. C., Hickey, D. G., Barnard, A. R., & MacLaren, R. E. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.005 · Cited by 112 · cited 1×
“259,260 In addition, a suitable codon optimization algorithm needs to avoid the addition of unwanted sequences such as alternative translation initiation codons, splicing donor and acceptor, or polyadenylation signals.”
Retinal gene therapy with a large MYO7A cDNA using adeno-associated virus
Lopes, V. S., Boye, S. E., Louie, C. M., Boye, S., Dyka, F., Chiodo, V, Fofo, H., Hauswirth, W. W., & Williams, D. S. (2013) · Gene Therapy · doi:10.1038/gt.2013.3 · Cited by 112
Shen, S., Horowitz, E. D., Troupes, A. N., Brown, S. M., Pulicherla, N., Samulski, R. J., Agbandje‐McKenna, M., & Asokan, A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.482380 · Cited by 112
Self-citationMonahan, P. E., Sun, J., Gui, T., Hu, G., Hannah, W. B., Wichlan, D. G., Wu, Z., Grieger, J. C., Li, C., Suwanmanee, T., et al. (2015) · Human Gene Therapy · doi:10.1089/hum.2014.106 · Cited by 108
Self-citationCecchini, S., Virág, T., & Kotin, R. M. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.250 · Cited by 108
Tanaka, A., Tumkosit, U., Nakamura, S., Motooka, D., Kishishita, N., Priengprom, T., Sa-ngasang, A., Kinoshita, T., Takeda, N., & Maeda, Y. (2017) · Journal of Virology · doi:10.1128/jvi.00432-17 · Cited by 108
Mary, B., Maurya, S., Arumugam, S., Kumar, V. S., & Jayandharan, G. R. (2019) · FEBS Journal · doi:10.1111/febs.15013 · Cited by 108
Chadeuf, G., Ciron, C., Moullier, P., & Salvetti, A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.06.003 · Cited by 107
Ling, C., Lu, Y., Kalsi, J. K., Jayandharan, G. R., Li, B., Ma, W., Cheng, B., Gee, S. W. Y., McGoogan, K. E., Govindasamy, L., et al. (2010) · Human Gene Therapy · doi:10.1089/hum.2010.075 · Cited by 107
Salmon, F., Grosios, K., & Petry, H. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2014.852065 · Cited by 106
Thomas, D. L., Wang, L., Niamke, J., Liu, J., Kang, W., Scotti, M. M., Ye, G., Veres, G., & Knop, D. R. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.004 · Cited by 106
Effects of Stuffer DNA on Transgene Expression from Helper-Dependent Adenovirus Vectors
Parks, R. J., Bramson, J. L., Wan, Y., Addison, C., & Graham, F. L. (1999) · Journal of Virology · doi:10.1128/jvi.73.10.8027-8034.1999 · Cited by 105
Host determinants of adeno-associated viral vector entry
Pillay, S., & Carette, J. E. (2017) · Current Opinion in Virology · doi:10.1016/j.coviro.2017.06.003 · Cited by 105
Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors
Colella, P., Trapani, I., Cesi, G., Sommella, A., Manfredi, A., Puppo, A., Iodice, C., Rossi, S., Simonelli, F., Giunti, M., et al. (2014) · Gene Therapy · doi:10.1038/gt.2014.8 · Cited by 103
The protelomerase of temperate Escherichia coli phage N15 has cleaving-joining activity
Deneke, J., Ziegelin, G., Lurz, R., & Lanka, E. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.7721 · Cited by 103
Minicircle‐DNA production by site specific recombination and protein–DNA interaction chromatography
Mayrhofer, P., Blaesen, M., Schleef, M., & Jechlinger, W. (2008) · The Journal of Gene Medicine · doi:10.1002/jgm.1243 · Cited by 102
Diverse IgG subclass responses to adeno‐associated virus infection and vector administration
Murphy, S. L., Li, H., Mingozzi, F., Sabatino, D. E., Hui, D. J., Edmonson, S. A., & High, K. A. (2009) · Journal of Medical Virology · doi:10.1002/jmv.21360 · Cited by 101
Pipe, S. W., Leebeek, F. W. G., Ferreira, V., Sawyer, E. K., & Pasi, J. (2019) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.08.015 · Cited by 101
Molecular Characterization of Adeno-Associated Viruses Infecting Children
Chen, C., Jensen, R. L., Schnepp, B. C., Connell, M. J., SHELL, R. D., Sferra, T. J., Bartlett, J. S., Clark, K. R., & Johnson, P. R. (2005) · Journal of Virology · doi:10.1128/jvi.79.23.14781-14792.2005 · Cited by 100
A Precise Chemical Strategy To Alter the Receptor Specificity of the Adeno‐Associated Virus
Kelemen, R. E., Mukherjee, R., Cao, X., Erickson, S. B., Zheng, Y., & Chatterjee, A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201604067 · Cited by 98
Adeno-associated Virus as a Mammalian DNA Vector
Salganik, M., Hirsch, M. L., & Samulski, R. J. (2015) · Microbiology Spectrum · doi:10.1128/microbiolspec.mdna3-0052-2014 · Cited by 97
Self-citationGabriel, N., Hareendran, S., Sen, D., Gadkari, R. A., Sudha, G., Selot, R., Hussain, M., Dhaksnamoorthy, R., Samuel, R., Srinivasan, N., et al. (2013) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.194 · Cited by 97
Li, C., Diprimio, N., Bowles, D. E., Hirsch, M. L., Monahan, P. E., Asokan, A., Rabinowitz, J., Agbandje-McKenna, M., & Samulski, R. J. (2012) · Journal of Virology · doi:10.1128/jvi.00675-12 · Cited by 96
Self-citationGene Therapy of mdx Mice With Large Truncated Dystrophins Generated by Recombination Using rAAV6
Odom, G. L., Gregorevic, P., Allen, J. M., & Chamberlain, J. S. (2011) · Molecular Therapy · doi:10.1038/mt.2010.205 · Cited by 95
Ghosh, A., Yue, Y., & Duan, D. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.122 · Cited by 95
A muscle-targeting peptide displayed on AAV2 improves muscle tropism on systemic delivery
Yu, C.-Y., Yuan, Z., Cao, Z., Wang, B., Qiao, C., Li, J., & Xiao, X. (2009) · Gene Therapy · doi:10.1038/gt.2009.59 · Cited by 94
Trapani, I., Toriello, E., de Simone, S., Colella, P., Iodice, C., Polishchuk, E. V., Sommella, A., Colecchi, L., Rossi, S., Simonelli, F., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv386 · Cited by 94
Körbelin, J., Sieber, T., Michelfelder, S., Lunding, L. P., Spies, E., Hunger, A., Alawi, M., Rapti, K., Indenbirken, D., Müller, O. J., et al. (2016) · Molecular Therapy · doi:10.1038/mt.2016.62 · Cited by 93
Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism
Powell, S. K., Khan, N., Parker, C. L., Samulski, R. J., Matsushima, G., Gray, S. J., & McCown, T. J. (2016) · Gene Therapy · doi:10.1038/gt.2016.62 · Cited by 92
Self-citationHelper Functions Required for Wild Type and Recombinant Adeno- Associated Virus Growth
Geoffroy, M., & Salvetti, A. (2005) · Current Gene Therapy · doi:10.2174/1566523054064977 · Cited by 90
Manufacturing of recombinant adeno-associated viruses using mammalian expression platforms
Robert, M., Chahal, P. S., Audy, A., Kamen, A., Gilbert, R., & Gaillet, B. (2017) · Biotechnology Journal · doi:10.1002/biot.201600193 · Cited by 89
mRNA secondary structure optimization using a correlated stem–loop prediction
Gaspar, P., Moura, G. R., Santos, M. A. S., & Oliveira, J. L. (2013) · Nucleic Acids Research · doi:10.1093/nar/gks1473 · Cited by 89
Hauck, B., Murphy, S. L., Smith, P. H., Qu, G., Liu, X., Zelenaia, O., Mingozzi, F., Sommer, J. M., High, K. A., & Wright, J. F. (2009) · Molecular Therapy · doi:10.1038/mt.2008.227 · Cited by 88
Koerber, J. T., Maheshri, N., Kaspar, B. K., & Schaffer, D. V. (2006) · Nature Protocols · doi:10.1038/nprot.2006.93 · Cited by 88
AAV capsid CD8+ T-cell epitopes are highly conserved across AAV serotypes
Hui, D. J., Edmonson, S. C., Podsakoff, G. M., Pien, G. C., Ivanciu, L., Camire, R. M., Ertl, H., Mingozzi, F., High, K. A., & Basner-Tschakarjan, E. (2015) · Molecular Therapy - Methods & Clinical Development · doi:10.1038/mtm.2015.29 · Cited by 84
Lecomte, E., Tournaire, B., Cogné, B., Dupont, J.-B., Lindenbaum, P., Martin-Fontaine, M., Broucque, F., Robin, C., Hebben, M., Merten, O.-W., et al. (2015) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2015.32 · Cited by 83
Self-citationChuah, M., Petrus, I., Bleser, P. D., Guiner, C. L., Gernoux, G., Adjali, O., Nair, N., Willems, J., Evens, H., Rincón, M. Y., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.114 · Cited by 83
Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier
Albright, B. H., Storey, C. M., Murlidharan, G., Castellanos Rivera, R. M., Berry, G. E., Madigan, V. J., & Asokan, A. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.017 · Cited by 82
Optimization of Retinal Gene Therapy for X-Linked Retinitis Pigmentosa Due to RPGR Mutations
Beltran, W. A., Cideciyan, A. V., Boye, S. E., Ye, G.-J., Iwabe, S., Dufour, V. L., Marinho, L. F., Swider, M., Kosyk, M. S., Sha, J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.004 · Cited by 82
Cited by
Current Strategies for Increasing Knock-In Efficiency in CRISPR/Cas9-Based Approaches
Leal, A., Herreno-Pachón, A., Benincore-Flórez, E., Karunathilaka, A., & Tomatsu, S. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052456 · Cited by 58
Innate immune sensing of adeno-associated virus vectors
Cao, D., Byrne, B. J., de Jong, Y. P., Terhorst, C., Duan, D., Herzog, R. W., & Kumar, S. R. P. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.040 · Cited by 50
Eukaryotic-driven directed evolution of Cas9 nucleases
(2024) · doi:10.1186/s13059-024-03215-9 · Cited by 15
Metadata
- Authors
- Pupo, A., Fernández, A., Low, S. H., François, A., Suárez-Amarán, L., & Samulski, R. J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2022-12
- Volume
- 30
- Issue
- 12
- Pages
- 3515-3541
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W4302028035
- Cited by
- 360
- References
- 335
- FWCI
- 38.64
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.